GLP-1

News

Study finds GLP-1 drugs may cut obesity-related cancers

Potentially adding to a lengthening list of positive health benefits of GLP-1 agonist drugs, a new study has suggested they may also reduce the risk of a bevy of cancers associated with bei

News

Study links Ozempic/Wegovy to sight-threatening disorder

Shares in Novo Nordisk and Eli Lilly have been under pressure after a study emerged suggesting that people taking a GLP-1 agonist had an elevated risk of a rare but serious eye condition.

News

Novo Nordisk's site in Clayton, North Carolina

Novo Nordisk pledges $4.1bn for US injectables plant

Novo Nordisk has gone up another gear in its drive to boost manufacturing capacity for its fast-growing GLP-1 agonist drugs, announcing plans to build a $4.1 billion fill-and-finish facilit

Market Access

Weight loss treatments bring in billions but capacity remain...

The high demand for weight loss treatments has made their rollout a staggered process.

Patients

Our expanding toolbox: Designing personalised strategies in ...

When I began practicing obesity medicine nearly 20 years ago, it was difficult for my patients to attain significant long-term weight loss without metabolic and bariatric surgery.

News

Metsera lands with $290m to take on obesity giants

Any company hoping to make headway in the market for obesity therapies will need deep pockets, so it’s an encouraging sign that start-up Metsera has launched with an impre

Study finds GLP-1 drugs may cut obesity-related cancers

Study links Ozempic/Wegovy to sight-threatening disorder

Novo Nordisk pledges $4.1bn for US injectables plant

Weight loss treatments bring in billions but capacity remain...

Our expanding toolbox: Designing personalised strategies in ...

Metsera lands with $290m to take on obesity giants

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

GLP-1

Editor's Picks